CCM
KZR

CAAS Capital Management’s Kezar Life Sciences KZR Stock Holding History

CAAS Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,444
Closed -$232K – 1287
2020
Q4 		$232K Buy
+4,444
New +$247K ﹤0.01% 753

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

CAAS Capital Management's KZR Position: Q1 2021 in Review

CAAS Capital Management sold out of Kezar Life Sciences (KZR) in Q1 2021, closing a stake of 4,444 shares — an estimated $232K sold.

CAAS Capital Management first reported a position in KZR in Q4 2020 and held it in 1 quarter. The position peaked at $232K in Q4 2020. 83 funds tracked by Wall St. Rank hold KZR as of Q1 2021.

  • CAAS Capital Management reported no remaining Kezar Life Sciences position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 4,444 Kezar Life Sciences shares in Q1 2021, an estimated $232K.
  • CAAS Capital Management first reported a position in Kezar Life Sciences in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Kezar Life Sciences position peaked at $232K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.